secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001140361-23-057341
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves ADMA's BIVIGAM for pediatric PI patients aged 2 and older
----------------------------------------------------------------------

- FDA approved supplemental BLA for BIVIGAM to treat primary humoral immunodeficiency (PI) in patients 2 years and older.
- Prior indication restricted to PI patients aged 12 years and older; label expansion opens new pediatric segment.
- Approval fulfills post-marketing commitment from original BLA; final pediatric study report completed.
- CEO Adam Grossman stated expanded label allows treating younger PI patients earlier in their treatment journey.
- ADMA will offer BIVIGAM as an FDA-approved option for pediatric PI patients aged 2+ immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123057341/0001140361-23-057341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123057341/ef20016477_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-057341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer